Life Technologies OpTmizer T-Cell growth medium cleared by FDA for trial use Life Technologies Corporation announced it has received FDA 510(k) clearance for its OpTmizer CTS T-Cell Expansion Tissue Culture Medium – a reagent that is now cleared as a Class II medical device and offers cost- and time-saving advantages for transitioning studies from the research bench to clinical trials. The OpTmizer CTS T-Cell Expansion Tissue Culture Medium is intended for human ex vivo tissue and cell culture processing application.
News For LIFE From The Last 14 Days
Check below for free stories on LIFE the last two weeks.
Life Technologies downgraded to Hold from Buy at Jefferies Jefferies downgraded Life Technologies citing the takeout bid by Thermo Fisher after assuming coverage of the stock. The firm raised its price target for shares to $76 from $58.
Subscribe for More Information
